Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amarin Corp Ads (AMRN)

Amarin Corp Ads (AMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,251,245
  • Shares Outstanding, K 357,214
  • Annual Sales, $ 229,210 K
  • Annual Income, $ -116,450 K
  • 60-Month Beta 1.07
  • Price/Sales 15.94
  • Price/Cash Flow N/A
  • Price/Book 10.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.03
  • Number of Estimates 6
  • High Estimate 0.01
  • Low Estimate -0.09
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +72.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.50 +4.65%
on 02/26/20
20.41 -20.53%
on 01/28/20
-4.00 (-19.78%)
since 01/24/20
3-Month
15.50 +4.65%
on 02/26/20
26.12 -37.90%
on 12/16/19
-4.25 (-20.76%)
since 11/26/19
52-Week
13.76 +17.88%
on 08/12/19
26.12 -37.90%
on 12/16/19
-3.79 (-18.94%)
since 02/26/19

Most Recent Stories

More News
Amarin's (AMRN) Q4 Earnings and Sales Surpass Estimates

Amarin's (AMRN) strong revenue growth in the fourth quarter is driven by solid demand for its cardiovascular drug, Vascepa.

REGN : 456.91 (+3.29%)
AZN : 47.40 (+0.68%)
HALO : 20.93 (+0.62%)
AMRN : 16.20 (-7.43%)
What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

SNY : 49.47 (+0.94%)
AMAG : 7.91 (-0.75%)
AMGN : 215.22 (+2.30%)
AMRN : 16.20 (-7.43%)
Amarin to Present at Two Upcoming Investor Conferences

Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at two upcoming investor conferences....

AMRN : 16.20 (-7.43%)
Amarin To Report Fourth Quarter and Full Year 2019 Results and Host Conference Call on February 25, 2020

Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's fourth quarter and full year 2019 financial results...

AMRN : 16.20 (-7.43%)
Electrophysiology Market Value Projected to Exceed $5 Billion by 2022

Various reports concerning the electrophysiology markets project that the market and its segments will continue to experience substantial growth in the coming years. Electrophysiology is the biomedical...

SENS : 1.52 (-6.17%)
BSGM : 3.81 (-4.75%)
PAVM : 2.49 (-15.02%)
ABT : 81.64 (+0.63%)
AMRN : 16.20 (-7.43%)
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

AMRN : 16.20 (-7.43%)
Amarin Honored by BioNJ with Innovator Award for VASCEPA(R) Development and Regulatory Approval

Amarin Corporation plc (NASDAQ:AMRN), announced today that BioNJ awarded Amarin with an Innovator Award in recognition of the approval of a new indication for VASCEPA(R) (icosapent ethyl) by the U.S. Food...

AMRN : 16.20 (-7.43%)
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know

Amarin (AMRN) closed the most recent trading day at $18.72, moving -0.58% from the previous trading session.

AMRN : 16.20 (-7.43%)
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Amarin (AMRN) closed at $19.04, marking a -1.4% move from the previous day.

AMRN : 16.20 (-7.43%)
HLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl)

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, is pleased to update investors that Vascepa(®)...

HLTRF : 16.5048 (-2.05%)
HLS.TO : 21.39 (-1.75%)
AMRN : 16.20 (-7.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade AMRN with:

Business Summary

Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies.

See More

Key Turning Points

2nd Resistance Point 18.38
1st Resistance Point 17.94
Last Price 16.20
1st Support Level 17.12
2nd Support Level 16.74

See More

52-Week High 26.12
Fibonacci 61.8% 21.40
Fibonacci 50% 19.94
Fibonacci 38.2% 18.48
Last Price 16.20
52-Week Low 13.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar